Search Results for: 68

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 23, 2024 08:15 ET ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to lead […]

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer Read More »

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

May 14, 2024 08:00 ET ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in a fireside chat at the

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference Read More »

Theriva™ Biologics participará en la conferencia virtual de salud de A.G.P.

May 14, 2024 08:00 ET ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), empresa diversificada de fase clínica que investiga tratamientos antineoplásicos y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que la dirección de la empresa ofrecerá una actualización corporativa y participará en un chat informal en

Theriva™ Biologics participará en la conferencia virtual de salud de A.G.P. Read More »

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024

May 08, 2024 06:39 ET – Se han presentado datos de primera línea del ensayo de fase 1 patrocinado por investigadores del VCN-01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario; el comité de vigilancia del estudio dictaminó que los resultados del ensayo son positivos – – Se han presentado datos preclínicos que demuestran

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024 Read More »

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

May 07, 2024 07:00 ET – Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study Monitoring Committee- -Presented preclinical data demonstrating the potential synergy between VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results Read More »

Theriva™ Biologics to Discuss the Trial Design for VIRAGE – a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma – at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 25, 2024 08:15 ET ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that, based on the strength of the science and its relevance, VIRAGE – the Phase 2b

Theriva™ Biologics to Discuss the Trial Design for VIRAGE – a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma – at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Read More »

Theriva™ Biologics hablará sobre el diseño del ensayo VIRAGE, un estudio clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia para el adenocarcinoma pancreático ductal, en la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO) de 2024

April 25, 2024 08:15 ET ROCKVILLE, Maryland, April 25, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha anunciado hoy que, basándose en la solidez de la ciencia y su relevancia, VIRAGE

Theriva™ Biologics hablará sobre el diseño del ensayo VIRAGE, un estudio clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia para el adenocarcinoma pancreático ductal, en la Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO) de 2024 Read More »

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

April 23, 2024 07:00 ET –Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children’s Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee– –Safety and clinical outcomes support the therapeutic potential of VCN-01 in retinoblastoma and emphasize VCN-01’s potential for use in diverse cancer indications– ROCKVILLE, Md., April 23,

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma Read More »

Theriva™ Biologics anuncia datos de primera línea positivos del ensayo de fase 1 patrocinado por investigadores de VCN-01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario

April 23, 2024 07:00 ET –El Comité de vigilancia del estudio ha determinado que el ensayo de fase 1 en colaboración con el Hospital Infantil Sant Joan de Déu Barcelona (SJD) tiene un resultado positivo– –La seguridad y los resultados clínicos respaldan el potencial terapéutico del VCN-01 en el retinoblastoma y subrayan el potencial del

Theriva™ Biologics anuncia datos de primera línea positivos del ensayo de fase 1 patrocinado por investigadores de VCN-01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario Read More »

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

April 22, 2024 16:35 ET – Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft– – The observed synergy emphasizes VCN-01’s potential in diverse chemotherapy combinations for improved efficacy in the treatment of pancreatic cancer– ROCKVILLE, Md., April 22, 2024 (GLOBE NEWSWIRE) — Theriva™ Biologics

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting Read More »